HLB Therapeutics Co.,Ltd. (KOSDAQ:115450)
South Korea
· Delayed Price · Currency is KRW 8,850.00
+190.00 (2.19%)
Apr 1, 2025, 3:30 PM KST
HLB Therapeutics Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Other Revenue | - | -0 | -0 | - | - | Upgrade
|
| Revenue | 54,932 | 52,591 | 42,403 | 43,586 | 42,930 | Upgrade
|
| Revenue Growth (YoY) | 4.45% | 24.03% | -2.72% | 1.53% | -27.20% | Upgrade
|
| Cost of Revenue | 44,953 | 45,406 | 33,682 | 38,579 | 36,464 | Upgrade
|
| Gross Profit | 9,979 | 7,184 | 8,721 | 5,007 | 6,466 | Upgrade
|
| Selling, General & Admin | 16,192 | 15,236 | 15,673 | 15,641 | 15,786 | Upgrade
|
| Other Operating Expenses | 301.46 | 183 | 273.11 | 240.04 | 218.66 | Upgrade
|
| Operating Expenses | 17,603 | 16,053 | 16,228 | 16,094 | 17,732 | Upgrade
|
| Operating Income | -7,624 | -8,869 | -7,507 | -11,087 | -11,267 | Upgrade
|
| Interest Expense | -1,964 | -1,112 | -5,146 | -1,160 | -4,254 | Upgrade
|
| Interest & Investment Income | 984.55 | 1,166 | 1,230 | 96.09 | 217.24 | Upgrade
|
| Earnings From Equity Investments | -3,153 | 802.4 | - | - | -909.06 | Upgrade
|
| Currency Exchange Gain (Loss) | 4,482 | 94.65 | 327.03 | 97.78 | -86.81 | Upgrade
|
| Other Non Operating Income (Expenses) | 1,363 | -3,430 | -1,334 | 15.88 | 5.87 | Upgrade
|
| EBT Excluding Unusual Items | -5,912 | -11,347 | -12,430 | -12,038 | -16,294 | Upgrade
|
| Gain (Loss) on Sale of Investments | -8,958 | 7,754 | 1,879 | -359.48 | 13.53 | Upgrade
|
| Gain (Loss) on Sale of Assets | -17.69 | 4.04 | -598.18 | -14.8 | 4.18 | Upgrade
|
| Asset Writedown | -8,037 | - | -424.08 | -4,632 | -1,953 | Upgrade
|
| Other Unusual Items | - | 624.11 | - | -720.83 | 829.12 | Upgrade
|
| Pretax Income | -22,926 | -2,965 | -11,573 | -17,764 | -17,401 | Upgrade
|
| Earnings From Continuing Operations | -22,926 | -2,965 | -11,573 | -17,764 | -17,401 | Upgrade
|
| Earnings From Discontinued Operations | -534.08 | -113.98 | -530.86 | - | - | Upgrade
|
| Net Income to Company | -23,460 | -3,079 | -12,104 | -17,764 | -17,401 | Upgrade
|
| Minority Interest in Earnings | 666.96 | 777.16 | 750.45 | 567.08 | 498.15 | Upgrade
|
| Net Income | -22,793 | -2,302 | -11,354 | -17,197 | -16,902 | Upgrade
|
| Net Income to Common | -22,793 | -2,302 | -11,354 | -17,197 | -16,902 | Upgrade
|
| Shares Outstanding (Basic) | 83 | 78 | 68 | 61 | 57 | Upgrade
|
| Shares Outstanding (Diluted) | 83 | 78 | 68 | 61 | 57 | Upgrade
|
| Shares Change (YoY) | 6.36% | 14.46% | 10.86% | 7.26% | 4.63% | Upgrade
|
| EPS (Basic) | -275.17 | -29.56 | -166.86 | -280.19 | -295.37 | Upgrade
|
| EPS (Diluted) | -275.17 | -29.56 | -166.86 | -280.19 | -295.37 | Upgrade
|
| Free Cash Flow | 650.79 | 3,025 | -12,204 | -12,091 | -11,736 | Upgrade
|
| Free Cash Flow Per Share | 7.86 | 38.84 | -179.37 | -196.99 | -205.09 | Upgrade
|
| Gross Margin | 18.17% | 13.66% | 20.57% | 11.49% | 15.06% | Upgrade
|
| Operating Margin | -13.88% | -16.86% | -17.70% | -25.44% | -26.24% | Upgrade
|
| Profit Margin | -41.49% | -4.38% | -26.78% | -39.45% | -39.37% | Upgrade
|
| Free Cash Flow Margin | 1.19% | 5.75% | -28.78% | -27.74% | -27.34% | Upgrade
|
| EBITDA | 467.85 | -389.34 | -5,841 | -9,386 | -10,566 | Upgrade
|
| EBITDA Margin | 0.85% | -0.74% | -13.78% | -21.54% | -24.61% | Upgrade
|
| D&A For EBITDA | 8,092 | 8,479 | 1,666 | 1,701 | 700.54 | Upgrade
|
| EBIT | -7,624 | -8,869 | -7,507 | -11,087 | -11,267 | Upgrade
|
| EBIT Margin | -13.88% | -16.86% | -17.70% | -25.44% | -26.24% | Upgrade
|
| Advertising Expenses | 0.69 | - | 0.21 | 7.07 | 32.42 | Upgrade
|
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.